Morgan Stanley Reiterates Overweight on Immunocore Hldgs, Maintains $79 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Andrew Galler reiterated an Overweight rating on Immunocore Holdings (NASDAQ: IMCR) and maintained a $79 price target.
June 26, 2023 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley analyst Andrew Galler reiterated an Overweight rating on Immunocore Holdings (NASDAQ: IMCR) and maintained a $79 price target.
The reiteration of an Overweight rating by Morgan Stanley's analyst Andrew Galler indicates a positive outlook for Immunocore Holdings. The maintained $79 price target suggests that the stock is expected to perform well in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100